

EDITORIAL ADVISORY PANEL

- | | |
|------------------------------------|-----------------------------------|
| N. H. Andersen (Aarhus) | L. Ng (Leicester) |
| C. Austin (Manchester) | T. Nyström (Stockholm) |
| D. Bhatnagar (Oldham) | M. J. O'Leary (Sydney) |
| I. Biaggioni (Nashville, TN) | T. Omland (Oslo) |
| C. E. Brightling (Leicester) | G. Parati (Milan) |
| A. Burt (Newcastle upon Tyne) | C. Pemberton (Christchurch, NZ) |
| D. Callen (Adelaide, S. Aus.) | P. Pérez-Martínez (Cordoba) |
| G. E. Callera (Ottawa) | S. Phillips (Hamilton) |
| J. D. Cameron (Dandenong, Vic.) | M. Rademaker (Christchurch, NZ) |
| V. Cameron (Christchurch, NZ) | C. Schalkwijk (Maastricht) |
| A. Carter (Leeds) | M. Schillinger (Vienna) |
| D. Chan (Perth, WA) | F. C. Schmalstieg, Jr (Galveston) |
| J. P. F. Chin-Dusting (Melbourne) | T. Shimosawa (Tokyo) |
| P. Chowienczyk (London) | C. C. Shoulders (London) |
| J. de Graaf (Nijmegen) | S. S. Smyth (Lexington, KY) |
| S. Duthie (Aberdeen) | I. Squire (Leicester) |
| S. Eguchi (Philadelphia) | J. Staessen (Leuven) |
| K. Evans (Stafford) | H. Stauss (Berlin) |
| A. Ferrante (North Adelaide) | I. Striz (Prague) |
| J. Floras (Toronto) | D.-F. Su (Shanghai) |
| L.-M. Gan (Goteburg) | G. Targher (Verona) |
| J. Garcia Estan (Murcia) | S. R. Thomas (Sydney) |
| B. Garner (Sydney) | N. C. Thomson (Glasgow) |
| G. J. Gibson (Newcastle upon Tyne) | V. Thongboonkerd (Bangkok) |
| S. Gough (Birmingham) | M. Tomaszewski (Leicester) |
| A. Graham (Glasgow) | H. Tomiyama (Tokyo) |
| G. Grassi (Milan) | R. C. Tostes (Augusta, GA) |
| D. J. Green (Nedlands, WA) | M. van der Giet (Berlin) |
| M. Grimm (Kogarah, NSW) | P. van der Harst (Groningen) |
| D. Gu (Beijing) | J. J. Van Lieshout (Amsterdam) |
| N. Haites (Aberdeen) | M. Verma (Bethesda) |
| J. D. Imig (Milwaukee) | J. Werner (Huddinge) |
| E. W. Inscho (Augusta, GA) | M. J. White (Birmingham) |
| J. T. Kielstein (Stanford, CA) | J. Wilson (Bankstown, NSW) |
| D. S. Kumararatne (Cambridge) | R. Woodman (Perth, WA) |
| T. Kuo (Hualien) | S. Ye (London) |
| P. Little (Melbourne) | C.-M. Yu (Hong Kong) |
| D. Lobo (Nottingham) | C. Zeng (Chongqing City) |
| R. A. Malik (Manchester) | C. Zhang (Newark) |
| P. G. McTernan (Coventry) | J. Zicha (Prague) |
| J. Mullins (Edinburgh) | |

Vascular Physiology
Diabetes
Obesity
Metabolism
Neurobiology
Ion Transport
Gastroenterology
Respiratory Medicine
Nutrition
Immunobiology
Molecular Cell Biology

Clinical **SCIENCE**

AN INTERNATIONAL JOURNAL OF CLINICAL & MOLECULAR INVESTIGATION

VOLUME 115 : 2008

EDITORIAL BOARD

Editor-in-Chief

R. Clinton Webb

Reviews Editor

Rhian Touyz

Associate Editors

David Adams

Nigel Brunskill

Philip Calder

Stephen Holgate

Jonathan Lamb

Chim Lang

Mhairi Macrae

Nilesh Samani

Gerald Watts

Editors

Louise Burrell

Peter Clifton

Kevin Croft

Alan Daugherty

Christian Delles

Jean-Francois Dufour

Peter Emery

Claudio Ferri

Dilys Freeman

Ian Godsland

Aroon Hingorani

Cathy Holt

Richard James

Anna Kurdowska

Maria Teresa La Rovere

Janice Marshall

Kevin McCully

Gary McVeigh

James Meschia

Giovanni Monteleone

Patricia Munroe

Sherif Nagueh

Philip Newsholme

Kevin O'Shaughnessy

Aled Phillips

Michael Polkey

Josep Redon

Åke Sjöholm

Allan Sniderman

Holger Stepan

Mark Swain

Ingo Tamm

Stephanie Watts

Michael Weis

Brenda Williams

Ian Young

**Published by Portland Press on behalf of the
Biochemical Society**

© The Biochemical Society 2008

ISSN 0143-5221

Printed in Great Britain by the Charlesworth Group, Wakefield

A U T H O R I N D E X

- | | | | |
|---|---|--|---|
| <u>A</u> dachi, M. 327–334
Ahn, H. 197–202
Ajamieh, H. H. 69–77
Akamura, M. 133–140
Alcaraz, A. 57–68
Alvarez, M. 25–33
Annerén, C. 43–55
Antoniadou, A. 189–196
Atucha, N. M. 57–68
Aurelio, P.-C. 245–253

<u>B</u> aessler, A. 301–308,
309–315
Beck-Sickinger, A. G. 13–23
Belch, J. J. F. 295–300
Beller, E. M. 273–281
Berndtson, D. 371–378
Blüher, M. 13–23
Boontham, P. 343–351
Brismar, K. 167–174
Brook, R. D. 175–187
Bruse, P. 309–315
Burghuber, O. C. 225–232
Burkhard, P. R. 25–33
Bye, A. 283–293

<u>C</u> abezas-Herrera, J.
245–253
Cámera, M. 343–351
Candelario-Jalil, E. 69–77
Chandran, P. 343–351
Charbonney, E. 25–33
Chen, C.-F. 335–342
Chen, R. 151–158
Chen, S. 151–158
Chevrolet, J.-C. 25–33
Chuthapisith, S. 343–351
Cohn, H. I. 79–89
Collins, P. 353–359
Coombes, J. S. 273–281
Cooney, L. M. 273–281
Cowan, P. J. 263
Cynober, L. 159–166

<u>D</u> alton, R. N. 361–369
d'Apice, A. J. F. 263 | <u>D</u> art, A. M. 99–106
Dayer, J.-M. 25–33
de Kleijn, D. P. V. 129–131
Doering, A. 301–308
Du, X.-J. 99–106
Dunger, D. B. 361–369

<u>E</u> ckhart, A. D. 79–89
Efendic, S. 167–174
Eickhoff, P. 225–232
Erdmann, J. 301–308,
309–315
Eremin, O. 343–351
Esechie, A. 91–97

<u>F</u> ang, L. 99–106
Fasshauer, M. 13–23
Fernández, O. S. L. 69–77
Ferris, R. 197–202
Fischer, M. 301–308,
309–315
Fontao, L. 25–33
Frostegard, J. 25–33

<u>G</u> albis-Martínez, L.
245–253
Gao, X.-M. 99–106
García-Estañ, J. 57–68
Garten, A. 13–23
Ge, D. 151–158
Gelato, M. C. 197–202
Gerbes, A. L. 69–77
Giamarellou, H. 189–196
Gonzalez, F. J. 107–127
Götz, A. 309–315
Gu, D. 151–158

<u>H</u> ahn, R. G. 371–378
Hansen, H. E. M. 283–293
Haram, P. M. 283–293
Harris, D. M. 79–89
Hawkins, H. 91–97
Hayward, C. S. 353–359
Heinrich, G. 283–293
Hemminki, J. 265–271 | <u>H</u> engstenberg, C. 301–308,
309–315
Hernández, D. 57–68
Hirano, T. 327–334
Hirata, K. 295–300
Hollingshead, H. E. 107–127
Hordern, M. D. 273–281
Horváth, E. M. 91–97
Huang, Z. 35–42
Hutri-Kähönen, N. 265–271

<u>I</u> konomidis, I. 189–196
Ilsley, C. D. 353–359
Immink, R. V. 255–262
Innocente, L. R. 317–326
Ishikawa, Y. 133–140
Itoh, T. 133–140
lyú, D. 57–68

<u>J</u> ames, R. 25–33
Jansson, L. 35–42
Jeron, A. 301–308
Juan, S.-H. 335–342
Juonala, M. 265–271

<u>K</u> aess, B. 301–308
Kähönen, M. 265–271
Kaihura, C. 219–224
Kapiotis, S. 225–232
Karemaker, J. M. 255–262
Kemi, O. J. 283–293
Khan, F. 295–300
Kim, Y.-S. 255–262
Kiss, L. 91–97
Knight, K. R. 263
Ko, M.-L. 335–342
Kodate, S. 327–334
König, I. R. 309–315
Kremastinos, D. T. 189–196

<u>L</u> aaksonen, M. 265–271
Lang, C. C. 295–300
Lasserre, V. 159–166
Latour-Pérez, J. 245–253
Lehtihet, M. 167–174
Lehtimäki, T. 265–271 | <u>L</u> ekakis, J. 189–196
Lemos, J. O. 317–326
Li, B. 151–158
Li, H. 151–158
Li, Y. 151–158
Lieb, W. 301–308, 309–315
Lim, Y. L. 99–106
Linsel-Nitschke, P. 309–315
Loennechen, J. P. 283–293
Lonardo, A. 1–12
Loria, P. 1–12
Lu, X. 151–158
Luo, Y. M. 233–244

<u>M</u> ach, F. 25–33
Marcovecchio, M. L.
361–369
Marniemi, J. 265–271
Martínez-Hernández, P.
245–253
Martínez-López de Castro,
A. 245–253
Marwick, T. H. 273–281
Mason, M. J. 353–359
Mayer, B. 309–315
McKechnie, A. 343–351
McNurlan, M. A. 197–202
Medack, A. 309–315
Meisinger, C. 301–308
Mensi, N. 25–33
Mikkilä, V. 265–271
Minami, Y. 133–140
Mitsching, S. 301–308
Miyazaki, A. 327–334
Moinard, C. 159–166
Mononen, N. 265–271
Morrison, W. A. 263
Mota, R. 57–68
Moxham, J. 233–244
Muslin, A. J. 203–218
Mynarcik, D. C. 197–202

<u>N</u> najjar, S. M. 283–293
Nakib, S. 159–166
Neureuther, K. 301–308
Neveux, N. 159–166 |
|---|---|--|---|

- | | | | |
|----------------------------|-----------------------------------|-------------------------------|------------------------------|
| Nicolaides, K. H. 219–224 | Qiang, B. 151–158 | Schjerve, I. E. 283–293 | Traber, D. L. 91–97 |
| Nieto-Cerón, S. 245–253 | Qurashi, S. 197–202 | Schreder, M. 225–232 | Tsiodras, S. 189–196 |
| Olah, G. 91–97 | Raitakari, O. 265–271 | Schunkert, H. 309–315 | Turck, N. 25–33 |
| Oliveira, J. M. 317–326 | Rallidis, L. 189–196 | Secher, N. H. 255–262 | Tyldum, G. A. 283–293 |
| Olsson, J. 371–378 | Räsänen, L. 265–271 | Sedlacek, K. 301–308 | V alipour, A. 225–232 |
| Ortiz, A. J. 57–68 | Reber, G. 25–33 | Shinkel, T. A. 263 | van Lieshout, J. J. 255–262 |
| Ortiz, M. C. 57–68 | Reinhard, W. 301–308 | Sjöholm, Å. 35–42 | Versteeg, D. 129–131 |
| Osowska, S. 159–166 | Riegger, G. 301–308 | Slørdahl, S. A. 283–293 | Viikari, J. 265–271 |
| P alios, J. 189–196 | Robins, A. 343–351 | Smith, G. L. 283–293 | Vuilleumier, N. 25–33 |
| Panagopoulos, P. 189–196 | Rodriguez-López, J. N.
245–253 | Sommer, G. 13–23 | W ang, L. 151–158 |
| Papadopoulos, A. 189–196 | Romeo-Meeuw, R. 263 | Sotiriadis, A. 219–224 | Watanabe, T. 327–334 |
| Pasterkamp, G. 129–131 | Rondó, P. H. C. 317–326 | Stark, K. 301–308, 309–315 | Webb, C. M. 353–359 |
| Patterson, D. 295–300 | Roux-Lombard, P. 25–33 | Stok, W. J. 255–262 | Weber, S. 301–308 |
| Peng, P.-H. 335–342 | Rowlands, B. J. 343–351 | Stølen, T. 283–293 | Widmer, B. 361–369 |
| Pereira, J. A. 317–326 | S aliba, S. 225–232 | Stumvoll, M. 13–23 | Wiedmann, S. 301–308 |
| Pesant, S. 79–89 | Samuel, C. S. 99–106 | Su, Y. 99–106 | Williams, P. 343–351 |
| Peters, J. M. 107–127 | Sanchez, J.-C. 25–33 | Suguro, T. 327–334 | Wisløff, U. 283–293 |
| Petzold, S. 13–23 | Satoh, M. 133–140 | Szabo, C. 91–97 | Wolzt, M. 225–232 |
| Polkey, M. I. 233–244 | Sattar, N. 141–150,
219–224 | T akahashi, Y. 133–140 | X u, G. 327–334 |
| Poulakou, G. 189–196 | Savvidou, M. D. 219–224 | Targher, G. 1–12 | Z hang, P. 151–158 |
| Preiss, D. 141–150 | | Tjønna, A. E. 283–293 | Zhao, Q. 151–158 |
| Prins, J. B. 273–281 | | Tolle, R. 301–308 | Ziegler, A. 309–315 |
| Pritchard, D. 343–351 | | Torres-Lanzas, J. 245–253 | |
| | | Tovar-Zapata, I. 245–253 | |

S U B J E C T I N D E X

- A**Acetylcholinesterase
airway surface fluid, lung cancer 245–253
- Acute lung injury
hydrogen sulfide, inflammation 97–97
- Adenosine
ischaemia/reperfusion, liver 69–77
- Adipokine
obesity, visfatin 13–23
- Adiponectin
HIV, insulin sensitivity 197–202
leptin, pregnancy 219–224
- Adult-type hypolactasia
atherosclerosis, lactase-phlorizin hydrolase 265–271
- Aerobic training
endothelial function, exercise 283–293
- Air pollution
cardiovascular disease, particulate matter 175–187
- Airway surface fluid
acetylcholinesterase, lung cancer 245–253
- Apolipoprotein A-I
autoimmunity, coronary artery disease 25–33
- Arachidonate 5-lipoxygenase-activating protein (*ALOX5AP*)
cardiovascular risk, myocardial infarction 309–315
- Arterial elasticity
birthweight, childhood 317–326
- Asymmetric dimethylarginine
insulin, Type 1 diabetes 361–369
- Atherosclerosis
adult-type hypolactasia,
lactase-phlorizin hydrolase 265–271
diabetic retinopathy, urotensin-II 327–334
liver fat, non-alcoholic fatty liver disease 1–12
- Autoimmunity
apolipoprotein A-I, coronary artery disease 25–33
- Autonomic neuropathy
cerebral autoregulation, Type 2 diabetes 255–262
- B**Birthweight
arterial elasticity, childhood 317–326
- Blood flow
gender, pancreatic islet 35–42
- Blood glucose
exercise, Type 2 diabetes 273–281
- C**Cardiovascular disease
air pollution, particulate matter 175–187
hypertrophy, mitogen-activated protein kinase 203–218
- Cardiovascular health
exercise, strength training 283–293
- Cardiovascular risk
arachidonate 5-lipoxygenase-activating protein (*ALOX5AP*),
myocardial infarction 309–315
myocardial infarction, peroxisome-proliferator-activated receptor α (*PPARA*) 301–308
- Cerebral autoregulation
autonomic neuropathy, Type 2 diabetes 255–262
- Childhood
arterial elasticity, birthweight 317–326
- Chronic obstructive pulmonary disease
systemic inflammation, vascular endothelial growth factor 225–232
- Cirrhosis
nitric oxide, peroxynitrite 57–68
- Citrulline
intestinal adaptation, parenteral nutrition 159–166
- D**Collagen
myocardial infarction, ventricular rupture 99–106
- Colon cancer
inflammatory bowel disease, peroxisome-proliferator-activated receptor 107–127
- Coronary artery disease
apolipoprotein A-I, autoimmunity 25–33
HIV, vascular function 189–196
- Coronary circulation
isoflavone, soya protein 353–359
laser Doppler imaging, vascular dysfunction 295–300
- E**Dendritic cell
quorum sensing, sepsis 343–351
- Diabetic retinopathy
atherosclerosis, urotensin-II 327–334
- Diaphragm
electromyography, oesophageal catheter 233–244
- F**Electromyography
diaphragm, oesophageal catheter 233–244
- Embryonic stem cell
intracellular signalling, tyrosine kinase 43–55
- Essential hypertension
gene variant, tyrosine hydroxylase 151–158
- Exercise
blood glucose, Type 2 diabetes 273–281
cardiovascular health, strength training 283–293
- I**Fluid balance
glucose/insulin infusion, metabolism 371–378

- Gender**
blood flow, pancreatic islet 35–42
- Gene variant**
essential hypertension, tyrosine hydroxylase 151–158
- Glucose/insulin infusion**
fluid balance, metabolism 371–378
- G-protein-coupled receptor**
hypertension, vascular smooth muscle 79–89
- Haem oxygenase**
ischaemia/reperfusion, retinal ganglion cell 335–342
- HIV**
adiponectin, insulin sensitivity 197–202
coronary artery disease, vascular function 189–196
- Hydrogen sulfide**
acute lung injury, inflammation 97–97
- Hypertension**
G-protein-coupled receptor, vascular smooth muscle 79–89
- Hypertrophy**
cardiovascular disease, mitogen-activated protein kinase 203–218
- Inflammation**
acute lung injury, hydrogen sulfide 97–97
myocardial infarction, Toll-like receptor 129–131, 133–140
- Inflammatory bowel disease**
colon cancer, peroxisome-proliferator-activated receptor 107–127
- Insulin**
asymmetric dimethylarginine, Type 1 diabetes 361–369
- Insulin-like growth factor-binding protein**
obesity, Type 2 diabetes 167–174
- Insulin resistance**
non-alcoholic fatty liver disease, obesity 141–150
- Insulin sensitivity**
adiponectin, HIV 197–202
- Intestinal adaptation**
citrulline, parenteral nutrition 159–166
- Intracellular signalling**
embryonic stem cell, tyrosine kinase 43–55
- Ischaemia/reperfusion**
adenosine, liver 69–77
haem oxygenase, retinal ganglion cell 335–342
- Isoflavone**
coronary circulation, soya protein 353–359
- Lactase-phlorizin hydrolase**
adult-type hypolactasia, atherosclerosis 265–271
- Laser Doppler imaging**
coronary circulation, vascular dysfunction 295–300
- Leptin**
adiponectin, pregnancy 219–224
- Liver**
adenosine, ischaemia/reperfusion 69–77
- Liver fat**
atherosclerosis, non-alcoholic fatty liver disease 1–12
- Lung cancer**
acetylcholinesterase, airway surface fluid 245–253
- Metabolism**
fluid balance, glucose/insulin infusion 371–378
- Mitogen-activated protein kinase**
cardiovascular disease, hypertrophy 203–218
- Myocardial infarction**
arachidonate 5-lipoxygenase-activating protein (*ALOX5AP*), cardiovascular risk 309–315
cardiovascular risk, peroxisome-proliferator-activated receptor α (*PPARA*) 301–308
collagen, ventricular rupture 99–106
inflammation, Toll-like receptor 129–131, 133–140
- Nitric oxide**
cirrhosis, peroxynitrite 57–68
- Non-alcoholic fatty liver disease**
atherosclerosis, liver fat 1–12
insulin resistance, obesity 141–150
- Obesity**
adipokine, visfatin 13–23
insulin resistance, non-alcoholic fatty liver disease 141–150
- insulin-like growth factor-binding protein, Type 2 diabetes 167–174
- Oesophageal catheter**
diaphragm, electromyography 233–244
- Pancreatic islet**
blood flow, gender 35–42
- Parenteral nutrition**
citrulline, intestinal adaptation 159–166
- Particulate matter**
air pollution, cardiovascular disease 175–187
- Peroxisome-proliferator-activated receptor**
colon cancer, inflammatory bowel disease 107–127
- Peroxisome-proliferator-activated receptor α (*PPARA*)**
cardiovascular risk, myocardial infarction 301–308
- Peroxynitrite**
cirrhosis, nitric oxide 57–68
- Preconditioning**
liver, oxidative stress 69–77
- Pregnancy**
adiponectin, leptin 219–224
- Quorum sensing**
dendritic cell, sepsis 343–351
- Retinal ganglion cell**
haem oxygenase, ischaemia/reperfusion 335–342
- Sepsis**
dendritic cell, quorum sensing 343–351
- Soya protein**
coronary circulation, isoflavone 353–359
- Strength training**
cardiovascular health, exercise 283–293
- Systemic inflammation**
chronic obstructive pulmonary disease, vascular endothelial growth factor 225–232
- Toll-like receptor**
inflammation, myocardial infarction 129–131, 133–140
- Type 1 diabetes**
asymmetric dimethylarginine, insulin 361–369

Type 2 diabetes	Urotensin-II	Vascular function
autonomic neuropathy, cerebral	atherosclerosis, diabetic	coronary artery disease, HIV
autoregulation 255–262	retinopathy 327–334	189–196
blood glucose, exercise 273–281		Vascular smooth muscle
insulin-like growth factor-binding		G-protein-coupled
protein, obesity 167–174		receptor, hypertension
Tyrosine hydroxylase	Vascular dysfunction	79–89
essential hypertension, gene variant	coronary circulation, laser	Ventricular rupture
151–158	Doppler imaging 295–300	collagen, myocardial infarction
Tyrosine kinase	Vascular endothelial growth	99–106
embryonic stem cell, intracellular	factor	Visfatin
signalling 43–55	chronic obstructive pulmonary	adipokine, obesity 13–23
	disease 225–232	